CN1615885A - Preparation method and application of long-acting progesterone injection implant - Google Patents
Preparation method and application of long-acting progesterone injection implant Download PDFInfo
- Publication number
- CN1615885A CN1615885A CNA2003101085691A CN200310108569A CN1615885A CN 1615885 A CN1615885 A CN 1615885A CN A2003101085691 A CNA2003101085691 A CN A2003101085691A CN 200310108569 A CN200310108569 A CN 200310108569A CN 1615885 A CN1615885 A CN 1615885A
- Authority
- CN
- China
- Prior art keywords
- progesterone
- preparation
- injection implant
- implant according
- organic solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002347 injection Methods 0.000 title claims abstract description 25
- 239000007924 injection Substances 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 239000007943 implant Substances 0.000 title claims description 17
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 title claims 29
- 229960003387 progesterone Drugs 0.000 title claims 14
- 239000000186 progesterone Substances 0.000 title claims 14
- BJJXHLWLUDYTGC-ANULTFPQSA-N Gestrinone Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](CC)([C@](CC3)(O)C#C)C=C3)C3=C21 BJJXHLWLUDYTGC-ANULTFPQSA-N 0.000 claims abstract description 15
- 229960004761 gestrinone Drugs 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 13
- 238000007920 subcutaneous administration Methods 0.000 claims abstract description 9
- 201000009273 Endometriosis Diseases 0.000 claims abstract description 6
- 239000000463 material Substances 0.000 claims abstract description 5
- 229920002988 biodegradable polymer Polymers 0.000 claims abstract 5
- 239000004621 biodegradable polymer Substances 0.000 claims abstract 5
- 239000000583 progesterone congener Substances 0.000 claims description 18
- 239000004005 microsphere Substances 0.000 claims description 17
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- 239000003960 organic solvent Substances 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 239000000375 suspending agent Substances 0.000 claims description 9
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 229960004400 levonorgestrel Drugs 0.000 claims description 6
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 5
- 239000004626 polylactic acid Substances 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- 206010046798 Uterine leiomyoma Diseases 0.000 claims description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- -1 polypropylene Polymers 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 238000010254 subcutaneous injection Methods 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 229960001786 megestrol Drugs 0.000 claims description 3
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims description 3
- 229960000417 norgestimate Drugs 0.000 claims description 3
- KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 229920000954 Polyglycolide Polymers 0.000 claims description 2
- 239000004743 Polypropylene Substances 0.000 claims description 2
- NOECSYBNZHIVHW-LKADTRSGSA-N [(2r,3as,3bs,5as,6r,8as,8br,10as)-2,6-diethynyl-3a,5a-dimethyl-2-propanoyloxy-1,3,3b,4,5,7,8,8a,8b,9,10,10a-dodecahydroindeno[5,4-e]inden-6-yl] propanoate Chemical compound C([C@]1(C)[C@](OC(=O)CC)(C#C)CC[C@H]1[C@@H]1CC2)C[C@@H]1[C@]1(C)[C@@H]2C[C@@](C#C)(OC(=O)CC)C1 NOECSYBNZHIVHW-LKADTRSGSA-N 0.000 claims description 2
- 235000010489 acacia gum Nutrition 0.000 claims description 2
- 238000007796 conventional method Methods 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 229920006237 degradable polymer Polymers 0.000 claims description 2
- 229960004976 desogestrel Drugs 0.000 claims description 2
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 claims description 2
- MJEMIOXXNCZZFK-UHFFFAOYSA-N ethylone Chemical compound CCNC(C)C(=O)C1=CC=C2OCOC2=C1 MJEMIOXXNCZZFK-UHFFFAOYSA-N 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 claims description 2
- 229960005352 gestodene Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000000178 monomer Substances 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 239000002077 nanosphere Substances 0.000 claims description 2
- 229940053934 norethindrone Drugs 0.000 claims description 2
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 claims description 2
- 239000004633 polyglycolic acid Substances 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 238000006116 polymerization reaction Methods 0.000 claims description 2
- 229920001155 polypropylene Polymers 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 239000007927 intramuscular injection Substances 0.000 claims 2
- 238000010255 intramuscular injection Methods 0.000 claims 2
- 239000007929 subcutaneous injection Substances 0.000 claims 2
- 229920002307 Dextran Polymers 0.000 claims 1
- 229920000084 Gum arabic Polymers 0.000 claims 1
- 229920002732 Polyanhydride Polymers 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 241000978776 Senegalia senegal Species 0.000 claims 1
- 239000000205 acacia gum Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000084 colloidal system Substances 0.000 claims 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 1
- 201000010260 leiomyoma Diseases 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- 239000007764 o/w emulsion Substances 0.000 claims 1
- 229920001610 polycaprolactone Polymers 0.000 claims 1
- 239000004632 polycaprolactone Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 abstract description 4
- 210000004185 liver Anatomy 0.000 abstract description 4
- 238000006243 chemical reaction Methods 0.000 abstract description 2
- 238000002474 experimental method Methods 0.000 abstract description 2
- 230000003111 delayed effect Effects 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 abstract 1
- 230000001072 progestational effect Effects 0.000 abstract 1
- 238000000935 solvent evaporation Methods 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 12
- 230000000694 effects Effects 0.000 description 6
- 210000004696 endometrium Anatomy 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 150000005846 sugar alcohols Polymers 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000002158 anti-implantation Effects 0.000 description 2
- 210000003756 cervix mucus Anatomy 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229960004911 nomegestrol Drugs 0.000 description 2
- KZUIYQJTUIACIG-YBZCJVABSA-N nomegestrol Chemical compound C1=C(C)C2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 KZUIYQJTUIACIG-YBZCJVABSA-N 0.000 description 2
- 229960002831 norgestrienone Drugs 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229960001584 promegestone Drugs 0.000 description 2
- QFFCYTLOTYIJMR-XMGTWHOFSA-N promegestone Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@@](C(=O)CC)(C)[C@@]1(C)CC2 QFFCYTLOTYIJMR-XMGTWHOFSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 238000011121 vaginal smear Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- XAVRSHOUEXATJE-FBQZJRKBSA-N 1-[(8s,9s,10r,13s,14s,17s)-3-cyclopentyloxy-10,13-dimethyl-2,7,8,9,11,12,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-17-yl]ethanone Chemical compound C([C@H]1[C@@H]2CC[C@@H]([C@]2(CC[C@@H]1[C@@]1(C)CC2)C)C(=O)C)C=C1C=C2OC1CCCC1 XAVRSHOUEXATJE-FBQZJRKBSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000008850 allosteric inhibition Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920006184 cellulose methylcellulose Polymers 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- VWQWXZAWFPZJDA-CGVGKPPMSA-N hydrocortisone succinate Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COC(=O)CCC(O)=O)[C@@H]4[C@@H]3CCC2=C1 VWQWXZAWFPZJDA-CGVGKPPMSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- GVDMJXQHPUYPHP-FYQPLNBISA-N norgestrienone Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)C#C)C=C3)C3=C21 GVDMJXQHPUYPHP-FYQPLNBISA-N 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 229950000796 quingestrone Drugs 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention introduces the preparation process of injection microballoon with PLGA, PLA or other biodegradable polymer as skeleton material and the progestational hormone, gestrinone, as model medicine, and through solvent evaporation. The microballoon may be injected to subcutaneous part or muscle for delayed releasing for over 15 days. The microballoon skeleton material inside body degrades gradually into small molecular matter excreted to outside the body. The gestrinone microballoon injection may be administrated conveniently and is superior to conventional tablet form, which is orally taken frequently to result in damage to liver and kidney and other negative reaction. Rat experiment shows that the preparation of the present invention may be used in treating endometriosis, etc.
Description
Technical field:
The present invention relates to a kind of long-acting progestogen injection implants preparation method and application.
Background technology:
Progestogen were the progestogen of moderate strength as gestrinone (Gestrinone, R2323, dl-18-methyl-norgestrienone, 18-first norgestrienone) originally, had stronger gestation and estrogen antagonist activity.Experiment showed, that this product has anti-implantation, the antiearly pregnancy effect is in the early stage ovulation inhibitory action that still has for oral use of menstrual cycle.Its anti-implantation, antiearly pregnancy effect and change cervical mucus denseness, the growth of interference endometrium influences the ovum speed of service and antagonism inner membrance progesterone receptor is relevant.Clinical former as visiting pill or postcoital contraceptive.
In recent years clinical research both at home and abroad finds that oral some progestogen still have the treatment endometriosis as gestrinone, the effect of diseases such as hysteromyoma, curative effect reliable (
1.Clin Exp Obstel Gynecol1996,23 (4): 198-204), (
2.Chinese medicine magazine (Taibei) 1996,58 (2): 89-96), (
3.Gynecol Obstel Invest 1997,43 (3): 192-194), (
4.J Med Assoc Thai 1999,82 (1): 9-14).
Present clinical progestogen only are that tablet is a kind of as the gestrinone dosage form, dosage 1: 5mg, 2.5mg.Be used for the endometriosis treatment, oral weekly secondary, each 2.5mg, 6 months course of treatment.Frequent drug administration is brought inconvenience to the patient.Forget medication and bring harmful effect to treatment.It should be noted that more progestogen such as gestrinone are oral, through liver, kidney metabolism and drainage, life-time service, to the human body Liver and kidney have certain infringement (Chen Xinqian chief editor, new pharmacology, the 15 edition, the People's Health Publisher, P597).
Summary of the invention:
The technical issues that need to address of the present invention are preparation method and the application that disclose a kind of long-acting progestogen injection implants, to overcome the defective that frequent drug administration that existing dosage form exists is brought inconvenience and the human body Liver and kidney had certain infringement to the patient.
Technical scheme of the present invention:
Long-acting progestogen injection implants of the present invention is a kind of in microgranule, microsphere, nanoparticle or the nanosphere; comprise the effective amount of actives progestogen and as the biological degradation polyalcohol of framework material; microsphere is that diameter is 10～120 microns a circular entity, and the preferred weight percent content of progestogen is 1～70%.
Said progestogen comprise gestrinone, gestodene (Gestrodene), nomegestrol (Nomegestrol), promegestone (Promegestone), norethindrone (Norgestrol), megestrol (Megestrol), norgestrel (Norgestrel), levonorgestrel (Levonorgestrel), Desogestrel (Desogestrol), norgestimate (Norgestimate), Norethisteroneoxime (NorehisteroneOxime), a kind of in quingestrone (Quingestanod) or the anorethindrane dipropionate (Anordrin) etc., preferred gestrinone.
Said biological degradation polyalcohol comprises polylactide-co-glycolide, polylactic acid, polyglycolic acid, pla-pcl, poly-anhydride, poly butyric ester-hydroxyl pentanoate copolymer, polypropylene glucosan, one or more of polylactic acid-polyglycol, preferred molecular weight range from 5,000 to 1,000,000 polymer, wherein said polylactide-co-glycolide monomer polymerization ratio is between 95: 5～5: 95, molecular weight is 10,000-500,000, the polylactic acid molecule amount is 5,000-300,000.
The invention still further relates to the above-mentioned preparation of treatment effective dose and the pharmaceutical composition of good biocompatibility and degradable carrier formation, above-mentioned preparation is adopted method well known in the art, can be prepared into subcutaneous easily or intramuscular dose, subcutaneous implant such as tablet, membrane, stick, pill.
Preparation of the present invention can be used for the treatment of diseases such as endometriosis and hysteromyoma effectively.The preparation method of the long-acting progestogen micro-balloon injection of the present invention comprises the steps:
Progestogen and biological degradation polyalcohol are dissolved in the organic solvent, after high-speed stirred, pour in the aqueous solution that contains suspending agent that is stirring, make under the temperature conditions that emulsion places 5～40 ℃, fling to organic solvent, from this mixture, adopt conventional method to collect microsphere then, be long-acting progestogen ejection preparation of the present invention.
Degradable polymer content in organic solvent is 1～500mg/ml;
Said organic solvent comprises dichloromethane, chloroform, ethyl acetate, ether or one or more;
Said suspending agent comprises polyvinyl alcohol, CMC, and PVP, eucolloid, as gelatin, arabic gum etc. a kind of, the content of suspending agent in aqueous solution is 1～50mg/ml;
The organic solvent that contains progestogen and biological degradation polyalcohol is 1: 1～500 (v/v) with the volume ratio that contains the aqueous solution of suspending agent.
The using method of preparation of the present invention is: the aseptic aqueous solution that will contain suspending agent injects microspheres prepared, after the mixing jolting, can be injected at subcutaneous or intramuscular, and dosage is pressed different pharmaceutical preparation description labelled amount and handled.
The treatment endometriosis, symptoms such as hysteromyoma can need the patient of above-mentioned treatment at minimum 15 days more than the interval.
Interior bag covers the medicine may command and discharges one period long period, and framework material can be degraded into inherent nontoxic small-molecule substance in the body automatically, is finally absorbed by body.
Above time of slow releasing pharmaceutical two weeks in vivo after the medication of this injection.Can reduce patient's medication number of times, both can make things convenient for patient treatment, reduce again that tablet is oral may to cause untoward reaction such as patient's hepatorenal damage.
The specific embodiment:
Embodiment 1
Get the 20mg gestrinone, 80mg polylactide-co-glycolide (lactide: Acetic acid, hydroxy-, bimol. cyclic ester=75: 25), be dissolved in the 3ml dichloromethane, under vigorous stirring, under (1000rpm) it is splashed in the 100ml 0.2% carboxymethyl cellulose sodium water solution, drip off the back and continue to stir 5-10 minute, reduce mixing speed then, in 25 ℃ of about 12h of evaporation to 300rpm, centrifugal, remove supernatant, precipitation is through filtration under diminished pressure, and a small amount of distilled water drip washing precipitates, reduced pressure at room temperature, microsphere diameter 40～120 μ m.
Embodiment 2
Get the 20mg gestrinone, the 80mg polylactic acid is dissolved in the 1ml dichloromethane, in high speed homogenizer, add 5ml 0.5%PVA aqueous solution, with 6000rpm rotating speed vigorous stirring 2min, pour in the 100ml 0.5%PVA aqueous solution,, centrifugal with 300rpm in 25 ℃ of about 12h of evaporation, remove supernatant, precipitation is through filtration under diminished pressure, a small amount of distilled water drip washing precipitation, reduced pressure at room temperature, microsphere diameter 30～80 μ m.
Embodiment 3
The inhibition test of rat oestrous cycle:
Method: select the rat of oestrous cycle rule to be divided into 2 groups, show at the vaginal secretions picture of rat to give following corresponding injection the same day of metoestrus (leukocyte) respectively:
Negative control group: subcutaneous (s.c.) injection of vehicle (n=5).
The microsphere group of embodiment 1: single dose s.c. injection drug release rate is the microsphere of 0.5mg/ week/kg, particle diameter 40～120 μ m, microsphere gestrinone content 25% (n=5).
After the injection, every day is the observed and recorded vaginal smear regularly, and the rat vagina sheet continues to show leukocyte, illustrate that the oestrous cycle is suppressed, as keratinocyte occurs, shows that then the oestrous cycle begins recovery, can judge the preparation duration of efficacy with the vaginal smear method.
The result: behind rat s.c. injection single dose microsphere 0.5mg/ week/kg, five rat vagina smears are respectively at 15 days, and 16 days, 16 days, 15 days, leukocyte appears all the time in 15 days, and garden cell and keratinocyte appear subsequently.Illustrate that its oestrous cycle was continued to have suppressed 15 days.Negative control group is not suppressed.
Embodiment 4
Rat endometrium dystopy curative effect:
Method: with reference to the Jones method (Acta Endocrinol 1984,106:282-88).Set up endometriotic rat model with the surgery autoplasty, a jiao of female rats uterus is cut, migrate on the abdominal wall.All around, open the abdominal cavity once more and check the Ectopic Endometrium upgrowth situation.Inhibition place Ectopic Endometrium well-grown and yellow liquid content person is arranged is the modelling winner, carry out following processing with the animal random packet after the measurement volumes:
Negative control group: rat back s.c. every day injecting normal saline (dividing 10 groups, every group of n=3).The microsphere group of embodiment 2: the disposable s.c. injectable microsphere of rat back, dosage is 0.5mg/ week/kg, particle diameter 30～80 μ m, microsphere gestrinone content 25% (dividing 10 groups, every group of n=3).
At the 2nd weekend, rat is put to death in anesthesia, opens the abdominal cavity, measures the Ectopic Endometrium volume, calculates suppression ratio.
Suppression ratio %=(1-V
2/ V
1) * 100%
V
1: transplant volume (mm before the treatment
2)
V
2: volume (mm is transplanted in the treatment back
2)
It the results are shown in Table 1.
From experimental result as seen, negative control group injection forebody-afterbody integration does not increase to 63.15 from 61.52, suppression ratio is-2.65%, microsphere group injection back volume reduces to 20.17 from 49.80 respectively, suppression ratio is 59.50%, there is significant difference (p＜0.05) in both, and body weight is not seen the increase phenomenon after the medication.
Table 1, gestrinone micro-balloon injection are to rat endometrium allosteric inhibition result of the test
| Group | ????1 | ????2 | ?????3 | ?????4 | ????5 | ?????6 | ????7 | ?????8 | ????9 | ????10 | ???11 | ???12 | |
| Empty to group | ??5.45 | ????4.45 | ?????5.22 | ?????4.95 | ???6.29 | ?????7.00 | ????2.82 | ?????3.02 | ????7.69 | ????3.88 | Meansigma methods | ???SD | The P value |
| ??5.01 | ????4.42 | ?????5.14 | ?????5.04 | ???4.72 | ?????5.27 | ????2.83 | ?????3.02 | ????6.89 | ????2.88 | ||||
| ??1.69 | ????2.36 | ?????2.21 | ?????2.56 | ???2.07 | ?????2.90 | ????2.16 | ?????1.64 | ????3.32 | ????2.05 | ||||
| The medicine front volume | ?46.14 | ???46.42 | ????59.30 | ?????63.87 | ??61.46 | ???106.98 | ???17.24 | ????14.96 | ??175.91 | ???22.91 | ??61.52 | ???48.59 | |
| ??2.82 | ????3.78 | ?????6.21 | ??????3.72 | ???5.29 | ?????7.19 | ????5.94 | ?????5.22 | ????4.87 | ????5.99 | ||||
| ??2.89 | ????4.36 | ?????6.21 | ??????4.99 | ???4.99 | ?????6.78 | ????5.14 | ?????5.09 | ????5.76 | ????5.37 | ||||
| ??1.09 | ????4.36 | ?????1.62 | ??????1.00 | ???3.36 | ?????2.89 | ????2.94 | ?????2.05 | ????1.19 | ????1.94 | ||||
| Volume behind the medicine | ??8.88 | ???71.86 | ????62.47 | ?????18.56 | ???88.69 | ???140.88 | ???89.94 | ????54.47 | ???33.38 | ???62.40 | ??63.15 | ???38.56 | |
| Volume factor | ??0.19 | ????1.55 | ?????1.05 | ??????0.29 | ????1.44 | ?????1.32 | ????5.22 | ????3.64 | ????0.19 | ????2.72 | ???1.76 | ????1.64 | |
| Body weight | 246.60 | ??249.30 | ???251.10 | ????266.60 | ??215.00 | ???276.70 | ??267.60 | ??240.40 | ??274.40 | ??258.50 | ?254.62 | ???18.51 | |
| The R2323 group | ??5.71 | ????5.99 | ?????5.08 | ??????5.69 | ????6.40 | ?????5.44 | ????6.10 | ????3.90 | ????4.60 | ????4.79 | Meansigma methods | ????SD | The P value |
| ??5.38 | ????5.99 | ?????5.09 | ??????5.49 | ????5.69 | ?????3.53 | ????6.18 | ????3.90 | ????6.34 | ????5.12 | ||||
| ??0.97 | ????2.60 | ?????1.50 | ??????0.80 | ????1.73 | ?????2.64 | ????2.30 | ????1.68 | ????2.44 | ????0.57 | ||||
| The medicine front volume | ?29.80 | ???93.29 | ????38.79 | ?????24.99 | ???63.00 | ????50.70 | ???86.71 | ???25.55 | ???71.16 | ???13.98 | ??49.80 | ???27.67 | |
| ??4.15 | ????4.45 | ?????5.78 | ??????4.58 | ????3.83 | ?????3.48 | ????4.59 | ????3.63 | ????5.92 | ????3.13 | ||||
| ??4.15 | ????3.35 | ?????5.12 | ??????4.88 | ????4.18 | ?????3.45 | ????4.58 | ????3.60 | ????5.32 | ????4.20 | ||||
| ??0.23 | ????0.85 | ?????1.27 | ??????0.80 | ????0.76 | ?????0.73 | ????0.50 | ????0.63 | ????2.63 | ????0.54 | ||||
| Volume behind the medicine | ??3.96 | ???12.67 | ????37.58 | ?????17.88 | ???12.17 | ?????8.76 | ???10.51 | ????8.23 | ???82.83 | ????7.10 | ??20.17 | ???23.93 | |
| Volume factor | ??0.13 | ????0.14 | ?????0.97 | ??????0.72 | ????0.19 | ?????0.17 | ????0.12 | ????0.32 | ????1.16 | ????0.51 | ??0.44 | ????0.38 | ?0.0238029 |
| Body weight | 202.30 | ??226.40 | ???228.20 | ????233.20 | ??250.40 | ???256.50 | ??238.20 | ??223.60 | ??258.80 | ??226.70 | ?234.43 | ???17.21 |
Claims (12)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2003101085691A CN1287798C (en) | 2003-11-13 | 2003-11-13 | Method for preparing long acting progestational hormone injection embedded agent and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2003101085691A CN1287798C (en) | 2003-11-13 | 2003-11-13 | Method for preparing long acting progestational hormone injection embedded agent and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1615885A true CN1615885A (en) | 2005-05-18 |
| CN1287798C CN1287798C (en) | 2006-12-06 |
Family
ID=34758624
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2003101085691A Expired - Fee Related CN1287798C (en) | 2003-11-13 | 2003-11-13 | Method for preparing long acting progestational hormone injection embedded agent and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1287798C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021207806A1 (en) * | 2020-04-17 | 2021-10-21 | Luiz Peracchi Edson | Long-lasting reabsorbable subcutaneous implant with controlled release of pre-concentrated pharmacologically active substance in polymer for the treatment of endometriosis |
-
2003
- 2003-11-13 CN CNB2003101085691A patent/CN1287798C/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021207806A1 (en) * | 2020-04-17 | 2021-10-21 | Luiz Peracchi Edson | Long-lasting reabsorbable subcutaneous implant with controlled release of pre-concentrated pharmacologically active substance in polymer for the treatment of endometriosis |
| EP4137126A4 (en) * | 2020-04-17 | 2024-05-22 | Luiz Peracchi, Edson | LONG-LASTING ABSORBABLE SUBCUTANEOUS IMPLANT WITH CONTROLLED RELEASE OF PRE-CONCENTRATED PHARMACOLOGICAL ACTIVE SUBSTANCE IN POLYMER FOR THE TREATMENT OF ENDOMETRIOSIS |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1287798C (en) | 2006-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3713237B2 (en) | Fulvestrant formulation | |
| ES2337129T3 (en) | MEDICINAL ADMINISTRATION SYSTEM UNDERSTANDING A TETRAHYDROXYLED STROGEN FOR USE IN HORMONAL ANTI-CONCEPTION. | |
| TWI336623B (en) | Pharmaceutical formulation for contraception and hormone-replacement therapy | |
| AU2004267956B2 (en) | Methods for the treatment of endometriosis | |
| US20120129819A1 (en) | Gel compositions for administration of pharmaceutically active compounds | |
| UA114106C2 (en) | METHOD OF TREATMENT OF PROGESTERON-DEPENDENT STATE BY ANTIPROGESTINE | |
| RU2482853C2 (en) | Pharmaceutical composition, method for preparing it and multiphase pharmaceutical preparation for ovulation inhibition in mammal | |
| WO2003004024A1 (en) | Injectable sustained-release microspheres of huperzine a compounds | |
| CN104902928A (en) | Co-micronisation product comprising ulipristal acetate | |
| Mei et al. | A novel mifepristone-loaded implant for long-term treatment of endometriosis: in vitro and in vivo studies | |
| CN102309438B (en) | Midazolam medicament composition as well as preparation method and application thereof | |
| CN1615885A (en) | Preparation method and application of long-acting progesterone injection implant | |
| WO2023174450A2 (en) | Silicone material, silicone tube, implant, pharmaceutical composition, and test method for amount of drug released | |
| CN1562042A (en) | Method for preparing long acting progestogen injection implant agent and use | |
| CN101455644A (en) | Long-acting composite contraception microspheres and preparation method thereof | |
| CN102655867B (en) | Parenteral pharmaceutical formulation in suspension, having sustained release, in low and ultralow dosage, in hormonal therapy in the climacteric syndrome | |
| RU2786452C1 (en) | Biodegradable polymer microparticle containing steroid-based drug and its production method | |
| US20120263784A1 (en) | Emergency contraceptive | |
| RU2411032C2 (en) | Drug preparation tilorone in suppositories | |
| WO2023115311A1 (en) | Sustained release preparation composition | |
| MXPA05013507A (en) | Process for the manufacture of stable shaped particles consisting of estradiol and cholesterol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20061206 Termination date: 20141113 |
|
| EXPY | Termination of patent right or utility model |